Review

anti dkk3 antibody (Bio X Cell)

Bio X Cell is a verified supplier

Bio X Cell manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Bio X Cell anti dkk3 antibody

<t>DKK3</t> safeguards acinar integrity and restrains dysplasia during PDAC onset. A) Experimental setup for ex vivo ADM assay B–E). (B and C) Brightfield images (B) and quantification of ductal structures (C) in acinar cultures treated or not with rDKK3 for three days. Arrows show ductal structures. Scale bar, 50 µm. (D) qRT‐PCR analysis of ductal marker gene expression in (A to C). (E and F) Brightfield images (E) and quantification of ductal structures F) in WT treated or not with <t>neutralizing</t> <t>anti‐DKK3</t> antibody and DD acinar cultures after four days. Arrows show ductal structures. Scale bar, 50 µm. G) qRT‐PCR analysis of ductal marker gene Krt19 expression in (E and F). H,I) DAVID‐based correlation analysis for down (H) and upregulated (I) genes of an RNA‐sequencing performed on acinar cultures after three days of ADM assay. J) Experimental setup for ex vivo ADM assay using neutralizing anti‐DKK3 antibody. K,L) Brightfield images (K) and quantification of ductal structures (L) in PPC (treated or not with neutralizing anti‐DKK3 antibody) and WT acinar cultures as in (J). Arrows show ductal structures. Scale bar, 50 µm. M) qRT‐PCR analysis of ductal marker gene Krt19 expression in PPC (treated or not with neutralizing anti‐DKK3 antibody) and WT acinar cultures as in (J). N) GSEA of the transcriptomics data showing upregulated pathways with FDR ≤ 0.05 in DD versus WT acinar cultures. Heatmap represents log 2 FC of top genes within the indicated gene sets. O) GSEA of the MAPK gene set in DD versus WT acinar cultures. Heatmap represents log 2 FC of top genes within the indicated gene sets. Data are means ± SEM. Each dot represents a mouse (C,D,F,G,L,M). Significance was calculated by an unpaired Student's t‐test. * p < 0.05; ** p < 0.01. ADM, acinar‐to‐ductal metaplasia; FC, fold change; FDR, false discovery rate; NES, normalized enrichment score.

Anti Dkk3 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti dkk3 antibody/product/Bio X Cell
Average 93 stars, based on 3 article reviews

anti dkk3 antibody - by Bioz Stars, 2026-06

93/100 stars

Images

1) Product Images from "DKK3 Initially Preserves Acinar Integrity Through MEK‐Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer"

Article Title: DKK3 Initially Preserves Acinar Integrity Through MEK‐Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer

Journal: Advanced Science

doi: 10.1002/advs.202417606

DKK3 safeguards acinar integrity and restrains dysplasia during PDAC onset. A) Experimental setup for ex vivo ADM assay B–E). (B and C) Brightfield images (B) and quantification of ductal structures (C) in acinar cultures treated or not with rDKK3 for three days. Arrows show ductal structures. Scale bar, 50 µm. (D) qRT‐PCR analysis of ductal marker gene expression in (A to C). (E and F) Brightfield images (E) and quantification of ductal structures F) in WT treated or not with neutralizing anti‐DKK3 antibody and DD acinar cultures after four days. Arrows show ductal structures. Scale bar, 50 µm. G) qRT‐PCR analysis of ductal marker gene Krt19 expression in (E and F). H,I) DAVID‐based correlation analysis for down (H) and upregulated (I) genes of an RNA‐sequencing performed on acinar cultures after three days of ADM assay. J) Experimental setup for ex vivo ADM assay using neutralizing anti‐DKK3 antibody. K,L) Brightfield images (K) and quantification of ductal structures (L) in PPC (treated or not with neutralizing anti‐DKK3 antibody) and WT acinar cultures as in (J). Arrows show ductal structures. Scale bar, 50 µm. M) qRT‐PCR analysis of ductal marker gene Krt19 expression in PPC (treated or not with neutralizing anti‐DKK3 antibody) and WT acinar cultures as in (J). N) GSEA of the transcriptomics data showing upregulated pathways with FDR ≤ 0.05 in DD versus WT acinar cultures. Heatmap represents log 2 FC of top genes within the indicated gene sets. O) GSEA of the MAPK gene set in DD versus WT acinar cultures. Heatmap represents log 2 FC of top genes within the indicated gene sets. Data are means ± SEM. Each dot represents a mouse (C,D,F,G,L,M). Significance was calculated by an unpaired Student's t‐test. * p < 0.05; ** p < 0.01. ADM, acinar‐to‐ductal metaplasia; FC, fold change; FDR, false discovery rate; NES, normalized enrichment score.

Figure Legend Snippet: DKK3 safeguards acinar integrity and restrains dysplasia during PDAC onset. A) Experimental setup for ex vivo ADM assay B–E). (B and C) Brightfield images (B) and quantification of ductal structures (C) in acinar cultures treated or not with rDKK3 for three days. Arrows show ductal structures. Scale bar, 50 µm. (D) qRT‐PCR analysis of ductal marker gene expression in (A to C). (E and F) Brightfield images (E) and quantification of ductal structures F) in WT treated or not with neutralizing anti‐DKK3 antibody and DD acinar cultures after four days. Arrows show ductal structures. Scale bar, 50 µm. G) qRT‐PCR analysis of ductal marker gene Krt19 expression in (E and F). H,I) DAVID‐based correlation analysis for down (H) and upregulated (I) genes of an RNA‐sequencing performed on acinar cultures after three days of ADM assay. J) Experimental setup for ex vivo ADM assay using neutralizing anti‐DKK3 antibody. K,L) Brightfield images (K) and quantification of ductal structures (L) in PPC (treated or not with neutralizing anti‐DKK3 antibody) and WT acinar cultures as in (J). Arrows show ductal structures. Scale bar, 50 µm. M) qRT‐PCR analysis of ductal marker gene Krt19 expression in PPC (treated or not with neutralizing anti‐DKK3 antibody) and WT acinar cultures as in (J). N) GSEA of the transcriptomics data showing upregulated pathways with FDR ≤ 0.05 in DD versus WT acinar cultures. Heatmap represents log 2 FC of top genes within the indicated gene sets. O) GSEA of the MAPK gene set in DD versus WT acinar cultures. Heatmap represents log 2 FC of top genes within the indicated gene sets. Data are means ± SEM. Each dot represents a mouse (C,D,F,G,L,M). Significance was calculated by an unpaired Student's t‐test. * p < 0.05; ** p < 0.01. ADM, acinar‐to‐ductal metaplasia; FC, fold change; FDR, false discovery rate; NES, normalized enrichment score.

Techniques Used: Ex Vivo, Quantitative RT-PCR, Marker, Gene Expression, Expressing, RNA Sequencing

Image Search Results

Establishment of DKK3-manipulated SiHa cell models with altered Wnt/β-catenin signaling activity. ( a , f ) Brightfield and fluorescence microscopy images after transfection with different lentivirus in SiHa cells cultured in medium (scale bar: 100 μm). ( b , g ) DKK3 mRNA expression in different treated cells ( n = 3). ( c - e , h - j ) Western blotting and corresponding quantitative expression analysis of DKK3 and β-catenin ( n = 3). Original blots are presented in Supplementary Fig. . * P < 0.05, ** P < 0.01, and *** P < 0.001 represent significant difference.

Journal: Scientific Reports

Article Title: Folic acid inhibits the Wnt/β-catenin pathway by upregulating DKK3 to exert anti-tumor effects in cervical squamous cell carcinoma

doi: 10.1038/s41598-025-32762-9

Figure Lengend Snippet: Establishment of DKK3-manipulated SiHa cell models with altered Wnt/β-catenin signaling activity. ( a , f ) Brightfield and fluorescence microscopy images after transfection with different lentivirus in SiHa cells cultured in medium (scale bar: 100 μm). ( b , g ) DKK3 mRNA expression in different treated cells ( n = 3). ( c - e , h - j ) Western blotting and corresponding quantitative expression analysis of DKK3 and β-catenin ( n = 3). Original blots are presented in Supplementary Fig. . * P < 0.05, ** P < 0.01, and *** P < 0.001 represent significant difference.

Article Snippet: Next, anti-DKK3 primary antibody (1:100 dilution; cat # 66758-1-lg, Proteintech, Wuhan, China) was applied to the sections for overnight incubation at 4 °C after a 30-min blocking step.

Techniques: Activity Assay, Fluorescence, Microscopy, Transfection, Cell Culture, Expressing, Western Blot

Cell proliferation, migration and invasion are affected by DKK3 expression in vitro. ( a , i ) CCK-8 assay detected the ability of cell proliferation ( n = 3). ( b - c , j - k ) Colony formation assay and count of different groups of SiHa cells( n = 3). ( d - e , l - m ) Representative wound healing assay images and analysis of different groups of SiHa cells ( n = 3). ( f - h , n - p ) Representative cell migration and invasion images and analysis of SiHa cells from different groups using transwell assay ( n = 3). * P < 0.05, ** P < 0.01, and *** P < 0.001 represent significant difference.

Journal: Scientific Reports

Article Title: Folic acid inhibits the Wnt/β-catenin pathway by upregulating DKK3 to exert anti-tumor effects in cervical squamous cell carcinoma

doi: 10.1038/s41598-025-32762-9

Figure Lengend Snippet: Cell proliferation, migration and invasion are affected by DKK3 expression in vitro. ( a , i ) CCK-8 assay detected the ability of cell proliferation ( n = 3). ( b - c , j - k ) Colony formation assay and count of different groups of SiHa cells( n = 3). ( d - e , l - m ) Representative wound healing assay images and analysis of different groups of SiHa cells ( n = 3). ( f - h , n - p ) Representative cell migration and invasion images and analysis of SiHa cells from different groups using transwell assay ( n = 3). * P < 0.05, ** P < 0.01, and *** P < 0.001 represent significant difference.

Techniques: Migration, Expressing, In Vitro, CCK-8 Assay, Colony Assay, Wound Healing Assay, Transwell Assay

FA inhibits cell viability, migration and invasion by upregulating DKK3 and reducing β-catenin protein abundance. ( a ) schematic illustration of the DKK3 regulation after cells treated with FA. ( b ) Cell viability of SiHa cells treated with different concentrations of FA ( n = 3). ( c )Cell viability of SiHa cells treated with different time course of FA ( n = 3). ( d ) Flow cytometry analysis for cell apoptosis of SiHa cells with different treatments ( n = 3). ( e ) Representative images for flow cytometry of SiHa cells with different treatments. ( f - g ) Representative wound healing assay images and analysis of FA treatment in SiHa cells ( n = 3). ( h ) Representative images of cell migration and invasion in SiHa cells treated with FA, using transwell assay. ( i - j ) Corresponding quantitative analysis of migration and invasion ( n = 3). (k) DKK3 mRNA levels in SiHa cells treated with different concentrations of FA ( n = 3). ( l – n ) Protein expression analysis of DKK3 and β‑catenin in SiHa cells under different FA treatments: representative western blot images (l) and corresponding quantification of DKK3 (m) and β‑catenin (n) ( n = 3). ( o ) Rescue experiments: DKK3 mRNA levels in DKK3‑knockdown SiHa cells treated with different concentrations of FA ( n = 3). ( p – r ) Rescue experiments: Protein expression analysis in DKK3‑knockdown SiHa cells under FA treatment: representative western blot images ( p ) and corresponding quantification of DKK3 ( q ) and β‑catenin ( r ) ( n = 3). Original blots are presented in Supplementary Fig. .* P < 0.05, ** P < 0.01, and *** P < 0.001 represent significant difference.

Journal: Scientific Reports

Article Title: Folic acid inhibits the Wnt/β-catenin pathway by upregulating DKK3 to exert anti-tumor effects in cervical squamous cell carcinoma

doi: 10.1038/s41598-025-32762-9

Figure Lengend Snippet: FA inhibits cell viability, migration and invasion by upregulating DKK3 and reducing β-catenin protein abundance. ( a ) schematic illustration of the DKK3 regulation after cells treated with FA. ( b ) Cell viability of SiHa cells treated with different concentrations of FA ( n = 3). ( c )Cell viability of SiHa cells treated with different time course of FA ( n = 3). ( d ) Flow cytometry analysis for cell apoptosis of SiHa cells with different treatments ( n = 3). ( e ) Representative images for flow cytometry of SiHa cells with different treatments. ( f - g ) Representative wound healing assay images and analysis of FA treatment in SiHa cells ( n = 3). ( h ) Representative images of cell migration and invasion in SiHa cells treated with FA, using transwell assay. ( i - j ) Corresponding quantitative analysis of migration and invasion ( n = 3). (k) DKK3 mRNA levels in SiHa cells treated with different concentrations of FA ( n = 3). ( l – n ) Protein expression analysis of DKK3 and β‑catenin in SiHa cells under different FA treatments: representative western blot images (l) and corresponding quantification of DKK3 (m) and β‑catenin (n) ( n = 3). ( o ) Rescue experiments: DKK3 mRNA levels in DKK3‑knockdown SiHa cells treated with different concentrations of FA ( n = 3). ( p – r ) Rescue experiments: Protein expression analysis in DKK3‑knockdown SiHa cells under FA treatment: representative western blot images ( p ) and corresponding quantification of DKK3 ( q ) and β‑catenin ( r ) ( n = 3). Original blots are presented in Supplementary Fig. .* P < 0.05, ** P < 0.01, and *** P < 0.001 represent significant difference.

Techniques: Migration, Quantitative Proteomics, Flow Cytometry, Wound Healing Assay, Transwell Assay, Expressing, Western Blot

Journal: Advanced Science

Article Title: DKK3 Initially Preserves Acinar Integrity Through MEK‐Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer

doi: 10.1002/advs.202417606

Figure Lengend Snippet: DKK3 safeguards acinar integrity and restrains dysplasia during PDAC onset. A) Experimental setup for ex vivo ADM assay B–E). (B and C) Brightfield images (B) and quantification of ductal structures (C) in acinar cultures treated or not with rDKK3 for three days. Arrows show ductal structures. Scale bar, 50 µm. (D) qRT‐PCR analysis of ductal marker gene expression in (A to C). (E and F) Brightfield images (E) and quantification of ductal structures F) in WT treated or not with neutralizing anti‐DKK3 antibody and DD acinar cultures after four days. Arrows show ductal structures. Scale bar, 50 µm. G) qRT‐PCR analysis of ductal marker gene Krt19 expression in (E and F). H,I) DAVID‐based correlation analysis for down (H) and upregulated (I) genes of an RNA‐sequencing performed on acinar cultures after three days of ADM assay. J) Experimental setup for ex vivo ADM assay using neutralizing anti‐DKK3 antibody. K,L) Brightfield images (K) and quantification of ductal structures (L) in PPC (treated or not with neutralizing anti‐DKK3 antibody) and WT acinar cultures as in (J). Arrows show ductal structures. Scale bar, 50 µm. M) qRT‐PCR analysis of ductal marker gene Krt19 expression in PPC (treated or not with neutralizing anti‐DKK3 antibody) and WT acinar cultures as in (J). N) GSEA of the transcriptomics data showing upregulated pathways with FDR ≤ 0.05 in DD versus WT acinar cultures. Heatmap represents log 2 FC of top genes within the indicated gene sets. O) GSEA of the MAPK gene set in DD versus WT acinar cultures. Heatmap represents log 2 FC of top genes within the indicated gene sets. Data are means ± SEM. Each dot represents a mouse (C,D,F,G,L,M). Significance was calculated by an unpaired Student's t‐test. * p < 0.05; ** p < 0.01. ADM, acinar‐to‐ductal metaplasia; FC, fold change; FDR, false discovery rate; NES, normalized enrichment score.

Article Snippet: Acinar cultures were treated with 10 μg mL −1 of rDKK3 (Sino Biological), with 0.025 ng mL −1 trametinib (Selleckchem), or with 40 μg mL −1 of monoclonal neutralizing anti‐DKK3 antibody (BioXCell).

Techniques: Ex Vivo, Quantitative RT-PCR, Marker, Gene Expression, Expressing, RNA Sequencing

The expression level of core genes. A DKK3 expression levels of the GSE69223 dataset and GSE46602 dataset; B WIF1 expression levels of the GSE69223 dataset and GSE46602 dataset; Compared with BPH group, * P < 0.05, ** P < 0.01, *** P < 0.001

Journal: Discover Oncology

Article Title: Potential role of DKK3 and WIF1 in prostate cancer: bioinformatics and clinical analysis

doi: 10.1007/s12672-025-03488-x

Figure Lengend Snippet: The expression level of core genes. A DKK3 expression levels of the GSE69223 dataset and GSE46602 dataset; B WIF1 expression levels of the GSE69223 dataset and GSE46602 dataset; Compared with BPH group, * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: The primary antibodies used in this study included an anti-DKK3 polyclonal antibody (Cat. No. 10365-1-AP, Sangon Biotech, China), an anti-WIF1 rabbit polyclonal antibody (Cat. No. 53483-1, SAB Biotech, USA), and an anti-GAPDH monoclonal antibody (Cat. No. 60004-1-Ig, Sangon Biotech, China).

Techniques: Expressing

Journal: Discover Oncology

Article Title: Potential role of DKK3 and WIF1 in prostate cancer: bioinformatics and clinical analysis

doi: 10.1007/s12672-025-03488-x

Figure Lengend Snippet: Immune correlation analysis of DKK3

Techniques:

GSEA enrichment analysis of DKK3. A GO-BP functional annotation analysis was conducted for DKK3. B GO-CC functional annotation analysis was conducted for DKK3. C GO-MF functional annotation analysis was conducted for DKK3. D KEGG pathway analysis was performed for DKK3

Journal: Discover Oncology

Article Title: Potential role of DKK3 and WIF1 in prostate cancer: bioinformatics and clinical analysis

doi: 10.1007/s12672-025-03488-x

Figure Lengend Snippet: GSEA enrichment analysis of DKK3. A GO-BP functional annotation analysis was conducted for DKK3. B GO-CC functional annotation analysis was conducted for DKK3. C GO-MF functional annotation analysis was conducted for DKK3. D KEGG pathway analysis was performed for DKK3

Techniques: Functional Assay

Correlation analysis of DKK3 and WIF1 expression with CTRP drug sensitivity and mRNA expression. A Correlation analysis of DKK3 expression with CTRP drug sensitivity and mRNA expression. B Correlation analysis of WIF1 expression with CTRP drug sensitivity and mRNA expression

Journal: Discover Oncology

Article Title: Potential role of DKK3 and WIF1 in prostate cancer: bioinformatics and clinical analysis

doi: 10.1007/s12672-025-03488-x

Figure Lengend Snippet: Correlation analysis of DKK3 and WIF1 expression with CTRP drug sensitivity and mRNA expression. A Correlation analysis of DKK3 expression with CTRP drug sensitivity and mRNA expression. B Correlation analysis of WIF1 expression with CTRP drug sensitivity and mRNA expression

Techniques: Expressing

Expression of DKK3 and WIF1 in BPH and PCa. A Expression of DKK3 in BPH. B Expression of DKK3 in PCa. C Expression of WIF1 in BPH. D Expression of WIF1 in PCa. E The protein expression of DKK3 and WIF 1 in BPH and PCa. Compared with BPH group, * P < 0.05, ** P < 0.01, *** P < 0.001

Journal: Discover Oncology

Article Title: Potential role of DKK3 and WIF1 in prostate cancer: bioinformatics and clinical analysis

doi: 10.1007/s12672-025-03488-x

Figure Lengend Snippet: Expression of DKK3 and WIF1 in BPH and PCa. A Expression of DKK3 in BPH. B Expression of DKK3 in PCa. C Expression of WIF1 in BPH. D Expression of WIF1 in PCa. E The protein expression of DKK3 and WIF 1 in BPH and PCa. Compared with BPH group, * P < 0.05, ** P < 0.01, *** P < 0.001

Techniques: Expressing

Fig. 1 High DKK3 expression is associated with worse patient survival across different cancer types. (A) DKK3 expression in normal adjacent tissues and tumors of patients from TCGA-PAAD, HNSC, THYM and DLBC. (B) The overall survival analysis of patients with high or low DKK3 expression from TCGA (pan-cancer), STAD, BLCA, GMB, HNSC and MESO. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as calculated by log-rank test or unpaired Student’s t-test

Journal: BMC cancer

Article Title: Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.

doi: 10.1186/s12885-025-14075-2

Figure Lengend Snippet: Fig. 1 High DKK3 expression is associated with worse patient survival across different cancer types. (A) DKK3 expression in normal adjacent tissues and tumors of patients from TCGA-PAAD, HNSC, THYM and DLBC. (B) The overall survival analysis of patients with high or low DKK3 expression from TCGA (pan-cancer), STAD, BLCA, GMB, HNSC and MESO. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as calculated by log-rank test or unpaired Student’s t-test

Article Snippet: They received intraperitoneal injections of 10 mg/kg of a mouse monoclonal DKK3 antibody (DKK3-4.22, BE0385, Bio X Cell), a mouse functional PD-1 antibody (BE0146, Bio X Cell), or a combination of both.

Techniques: Expressing

Fig. 2 DKK3 expression is associated with immunosuppressive TME across different cancer types. (A) The interrelation of DKK3 expression with the infiltration percentage of CD8+ T cells in tumor samples from TCGA-BRCA, COAD, ESCA, LUSC and PAAD. (B) The interrelation of DKK3 expression with the infiltration percentage of Th1 cells in tumor samples from TCGA-BRCA, COAD, KICH, LGG and STAD. (C) The interrelation of DKK3 expression with the infiltration percentage of Treg cells in tumor samples from TCGA-BLCA, COAD, LUAD, PAAD and PRAD. (D) The interrelation of DKK3 expression with the infiltration percentage of M2 macrophages in tumor samples from TCGA-BLCA, COAD, KICH, READ and TGCT. (E) The interrelation of DKK3 expression with the infiltration percentage of MDSCs in tumors from TCGA-CESC, ESCA, HNSC, MESO and SKCM

Journal: BMC cancer

Article Title: Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.

doi: 10.1186/s12885-025-14075-2

Figure Lengend Snippet: Fig. 2 DKK3 expression is associated with immunosuppressive TME across different cancer types. (A) The interrelation of DKK3 expression with the infiltration percentage of CD8+ T cells in tumor samples from TCGA-BRCA, COAD, ESCA, LUSC and PAAD. (B) The interrelation of DKK3 expression with the infiltration percentage of Th1 cells in tumor samples from TCGA-BRCA, COAD, KICH, LGG and STAD. (C) The interrelation of DKK3 expression with the infiltration percentage of Treg cells in tumor samples from TCGA-BLCA, COAD, LUAD, PAAD and PRAD. (D) The interrelation of DKK3 expression with the infiltration percentage of M2 macrophages in tumor samples from TCGA-BLCA, COAD, KICH, READ and TGCT. (E) The interrelation of DKK3 expression with the infiltration percentage of MDSCs in tumors from TCGA-CESC, ESCA, HNSC, MESO and SKCM

Techniques: Expressing

Fig. 3 DKK3 inhibits CD8+ T cell activation and Th1 differentiation ex vivo. (A) Primary CD4+ or CD8+ T cells isolated and sorted by MACS were treated with IL-2 (20 ng/mL) and IL-15 (20 ng/mL), and co-cultured with DKK3 recombinant protein (50 ng/mL). After 48 h co-culture, the activation level of CD8+ T cells was measured by the expressions of (B) CD25, (C) CD69, (D) CD107a and (E) IFN-γ by flow cytometry. And the expression of (F) T-bet and (G) GATA3 in CD4+ T cells were measured by flow cytometry. The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Journal: BMC cancer

Article Title: Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.

doi: 10.1186/s12885-025-14075-2

Figure Lengend Snippet: Fig. 3 DKK3 inhibits CD8+ T cell activation and Th1 differentiation ex vivo. (A) Primary CD4+ or CD8+ T cells isolated and sorted by MACS were treated with IL-2 (20 ng/mL) and IL-15 (20 ng/mL), and co-cultured with DKK3 recombinant protein (50 ng/mL). After 48 h co-culture, the activation level of CD8+ T cells was measured by the expressions of (B) CD25, (C) CD69, (D) CD107a and (E) IFN-γ by flow cytometry. And the expression of (F) T-bet and (G) GATA3 in CD4+ T cells were measured by flow cytometry. The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Techniques: Activation Assay, Ex Vivo, Isolation, Cell Culture, Recombinant, Co-Culture Assay, Flow Cytometry, Expressing

Fig. 4 DKK3 blockade controls tumor growth in different mouse cancer models. (A-B) The tumor volume and overall survival of LLC-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (C-D) The tumor volume and overall survival of MC38-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (E-F) The tumor volume and overall survival of MFC-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (G-H) The tumor volume and overall survival of Pan02-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Journal: BMC cancer

Article Title: Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.

doi: 10.1186/s12885-025-14075-2

Figure Lengend Snippet: Fig. 4 DKK3 blockade controls tumor growth in different mouse cancer models. (A-B) The tumor volume and overall survival of LLC-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (C-D) The tumor volume and overall survival of MC38-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (E-F) The tumor volume and overall survival of MFC-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). (G-H) The tumor volume and overall survival of Pan02-challenged mice with or without DKK3-4.22 treatment (10 mg/kg). The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Techniques:

Fig. 5 DKK3 blockade remodels the tumor immune microenvironment of different cancers. At the treatment endpoint, the percentages of (A) CD8+/ CD3+ cells, (B) IFNγ+/CD8+ T cells, (C) T-bet+/CD8+ cells, (D) CD164+/F4/80+ cells, and (E) Gr-1+/CD11b+ cells in tumors of the syngeneic LLC, MC38, MFC and Pan02 models were detected by flow cytometry (n = 5 per group). The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Journal: BMC cancer

Article Title: Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.

doi: 10.1186/s12885-025-14075-2

Figure Lengend Snippet: Fig. 5 DKK3 blockade remodels the tumor immune microenvironment of different cancers. At the treatment endpoint, the percentages of (A) CD8+/ CD3+ cells, (B) IFNγ+/CD8+ T cells, (C) T-bet+/CD8+ cells, (D) CD164+/F4/80+ cells, and (E) Gr-1+/CD11b+ cells in tumors of the syngeneic LLC, MC38, MFC and Pan02 models were detected by flow cytometry (n = 5 per group). The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Techniques: Flow Cytometry

Fig. 6 Combined blockade of DKK3 and PD-1 triggers synergistic anti-tumor effects. (A) The tumor volume of LLC-challenged mice with DKK3-4.22 (10 mg/kg) and / or anti-PD-1 treatment (10 mg/kg). (B) The tumor volume in each group of the LLC mouse model. The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Journal: BMC cancer

Article Title: Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.

doi: 10.1186/s12885-025-14075-2

Figure Lengend Snippet: Fig. 6 Combined blockade of DKK3 and PD-1 triggers synergistic anti-tumor effects. (A) The tumor volume of LLC-challenged mice with DKK3-4.22 (10 mg/kg) and / or anti-PD-1 treatment (10 mg/kg). (B) The tumor volume in each group of the LLC mouse model. The unpaired student’s t-test is used to determine whether data with error bars are significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001)

Techniques:

Review

Structured Review

Images

1) Product Images from "DKK3 Initially Preserves Acinar Integrity Through MEK‐Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer"

Similar Products

Image Search Results